全文获取类型
收费全文 | 2521篇 |
免费 | 194篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 29篇 |
儿科学 | 79篇 |
妇产科学 | 28篇 |
基础医学 | 232篇 |
口腔科学 | 37篇 |
临床医学 | 310篇 |
内科学 | 813篇 |
皮肤病学 | 16篇 |
神经病学 | 105篇 |
特种医学 | 275篇 |
外科学 | 263篇 |
综合类 | 78篇 |
一般理论 | 2篇 |
预防医学 | 210篇 |
眼科学 | 34篇 |
药学 | 81篇 |
中国医学 | 5篇 |
肿瘤学 | 128篇 |
出版年
2021年 | 22篇 |
2020年 | 18篇 |
2019年 | 13篇 |
2018年 | 39篇 |
2017年 | 24篇 |
2016年 | 32篇 |
2015年 | 44篇 |
2014年 | 42篇 |
2013年 | 52篇 |
2012年 | 75篇 |
2011年 | 80篇 |
2010年 | 72篇 |
2009年 | 91篇 |
2008年 | 114篇 |
2007年 | 98篇 |
2006年 | 96篇 |
2005年 | 84篇 |
2004年 | 77篇 |
2003年 | 106篇 |
2002年 | 80篇 |
2001年 | 66篇 |
2000年 | 90篇 |
1999年 | 65篇 |
1998年 | 66篇 |
1997年 | 70篇 |
1996年 | 82篇 |
1995年 | 73篇 |
1994年 | 54篇 |
1993年 | 67篇 |
1992年 | 60篇 |
1991年 | 35篇 |
1990年 | 42篇 |
1989年 | 65篇 |
1988年 | 65篇 |
1987年 | 73篇 |
1986年 | 68篇 |
1985年 | 55篇 |
1984年 | 37篇 |
1983年 | 25篇 |
1982年 | 33篇 |
1981年 | 19篇 |
1980年 | 13篇 |
1979年 | 17篇 |
1977年 | 27篇 |
1976年 | 22篇 |
1975年 | 28篇 |
1974年 | 26篇 |
1973年 | 19篇 |
1972年 | 15篇 |
1971年 | 15篇 |
排序方式: 共有2725条查询结果,搜索用时 31 毫秒
1.
2.
Differentiation of cardiac murmurs by dynamic auscultation 总被引:1,自引:0,他引:1
The techniques described in this monograph will aid in the accurate identification of the origin of a cardiac murmur or abnormal heart sound. They do not necessarily reveal the presence or severity of cardiac disease. No maneuver is 100% accurate in elucidation of cardiac abnormalities, and a given maneuver's effectiveness varies in its application. The systematic application of a combination of maneuvers improves the accuracy of diagnosis. Auscultatory findings must be interpreted with consideration of the total clinical examination including history, other physical findings, ECG, chest x-ray, and possibly an echocardiogram. Thus, the careful physiological approach to the physical examination represents a powerful noninvasive tool that can be used in combination with other information to accurately diagnose cardiac disease in many patients and efficiently direct further evaluation when necessary. 相似文献
3.
M. F. O'Rourke 《Internal medicine journal》2009,39(5):344-345
4.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
5.
OBJECTIVE: Based on recent safety and efficacy data, combined with the known pharmacokinetic parameters of aminoglycosides in the newborn, once-daily gentamicin should be preferable to the many other dosing regimens currently in use. Although there are growing data to support its use in term newborns, experience with preterm infants is more limited. In our Neonatal Intensive Care Unit, we experienced difficulties regarding complicated dosing regimens, actual dosing errors, and the tendency to check trough and peak levels around the third dose for infants receiving only a 48 hour course. Therefore, we conducted a quality improvement initiative in which we developed and tested a clinical practice guideline for the use of once-daily gentamicin for preterm and term infants that we hoped would yield trough and peak levels in our target range. METHODS: We combined a review of the published English language literature with pharmacokinetic analysis of our own data prior to initiation of this new regimen to design the following dosing regimen: <35 weeks gestation: 3 mg/kg q 24 hours, > or =35 weeks gestation: 4 mg/kg q 24 hours. Our goal serum levels were a trough < or =2 microg/ml and a peak between 6 and 12 microg/ml. We collected and analyzed trough and peak levels from all infants receiving this dosing regimen in the first week of life for at least 72 hours between 3/1/99 and 12/31/00. RESULTS: In total, 214 babies met our inclusion criteria, 75 of whom were <35 weeks gestation. 100% of babies of all gestational ages had a nontoxic trough level. For infants <35 weeks gestation, 79% had a therapeutic peak level, with a mean value of 6.8 microg/ml. For infants of at least 35 weeks gestation, 93% had a therapeutic peak level, with a mean value of 8.4 microg/ml. 92% of nontherapeutic peaks were too low. CONCLUSION: This study of once-daily gentamicin represents the largest sample size of pre-term infants published to date. The proposed regimen is simple and yields a high proportion of desirable levels. We recommend it for use in preterm and term newborns. 相似文献
6.
7.
8.
9.
10.